Article
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
Scientific reports - 24 Jan 2022
Chionh Fiona, Gebski Val, Al-Obaidi Sheren J, Mooi Jennifer K, Bruhn Maressa A, Lee Chee K, Chüeh Anderly C, Williams David S, Weickhardt Andrew J, Wilson Kate, Scott Andrew M, Simes John, Hardingham Jennifer E, Price Timothy J, Mariadason John M, Tebbutt Niall C
Abstract excerpt
The phase III MAX clinical trial randomised patients with metastatic colorectal cancer (mCRC) to receive first-line capecitabine chemotherapy alone or in combination with the anti-VEGF-A antibody bevacizumab (± mitomycin C). We utilised this cohort to examine whether single nucleotide polymorphisms (SNPs) in VEGF-A, VEGFR1, and VEGFR2 are predictive of efficacy outcomes with bevacizumab or the development of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.